| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12928-014-0277-1 |
| P698 | PubMed publication ID | 24935072 |
| P2093 | author name string | Y Hiasa | |
| R Teng | |||
| H Emanuelsson | |||
| P2860 | cites work | Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug | Q28187017 |
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin | Q28195019 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers | Q33163280 | ||
| Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry | Q33447413 | ||
| Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers | Q34019342 | ||
| Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. | Q34020220 | ||
| Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects | Q34120974 | ||
| Genetic determinants of response to clopidogrel and cardiovascular events | Q34910210 | ||
| Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes | Q37959155 | ||
| Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. | Q38056525 | ||
| Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study | Q38479485 | ||
| Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects | Q43187673 | ||
| Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. | Q45954831 | ||
| Clopidogrel and the concept of high-risk pharmacokinetics. | Q46034382 | ||
| Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) tria | Q46068914 | ||
| Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention | Q46184554 | ||
| In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics | Q48302970 | ||
| P433 | issue | 4 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 324-333 | |
| P577 | publication date | 2014-06-17 | |
| P1433 | published in | Cardiovascular intervention and therapeutics | Q27724051 |
| P1476 | title | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. | |
| P478 | volume | 29 |
| Q59799852 | Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis |
| Q49540317 | Evaluation of pharmacokinetic, pharmacodynamic, efficacy, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review |
| Q48348319 | Higher Risk of Bleeding in Asians Presenting With ST-Segment Elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database. |
| Q37198888 | Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial |
| Q42023858 | Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease |
| Q42694846 | Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects |
| Q64079786 | Pharmacokinetic and Pharmacogenetic Factors Contributing to Platelet Function Recovery After Single Dose of Ticagrelor in Healthy Subjects |
| Q92717119 | Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics |
| Q52682104 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. |
| Q27006031 | Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update |
| Q38352069 | Ticagrelor: a review of its use in adults with acute coronary syndromes |
Search more.